Deal Library / Pharma BD Deal Intelligence

Boehringer Ingelheim GmbH — Pharma Deals

The Pharma Closeout tracks 6 deals, $5.4B in disclosed deal value, 2 with a post-close Outcome Score for Boehringer Ingelheim GmbH.

Median Critic Score: 77  ·  Median Outcome Score: 52

Best outcome: Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) (77)  ·  Weakest outcome: Boehringer Ingelheim GmbH / NBE Therapeutics (28)

All 6 deals

• Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) — 2011 · Worked — the deal delivered on its rationale.
• Boehringer Ingelheim GmbH / NBE Therapeutics — 2020 · $1.5B · Did not work — the deal failed to deliver.
• Boehringer Ingelheim GmbH / NBE-Therapeutics AG — 2020 · $1.4B
• Boehringer Ingelheim GmbH / AMAL Therapeutics SA — 2019 · $366M
• Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. — 2019 · $1.2B
• Boehringer Ingelheim GmbH / Yuhan Corporation — 2019 · $870M

← Deal Library  ·  Interactive search  ·  How we score deals